Universal Vaccines: Fighting Viruses, Bacteria, and Allergens

Researchers from Stanford Medicine and other U.S. Institutions have developed a nasal spray vaccine that provides broad protection against a diverse range of respiratory threats, including viruses, bacteria, and allergens. The study, published on February 19, 2026, in the journal Science, demonstrates a departure from traditional vaccine design by focusing on the body’s immune response rather than targeting a specific pathogen.

The vaccine, identified as GLA-3M-052-LS+OVA, was tested in mice and showed the ability to protect the lungs for several months. Unlike conventional vaccines that rely on antigen specificity—mimicking a specific part of a pathogen like the spike protein of SARS-CoV-2—this new formula works by supercharging the innate immune system to create a first line of defense.

Protection Against Viruses and Bacteria

In the study, three doses of the nasal spray protected mice from SARS-CoV-2 and other coronaviruses for a period of three months. The researchers observed that the viral load in the lungs of vaccinated mice was reduced 700-fold compared to those that were unvaccinated.

The vaccine also significantly accelerated the immune response. While the adaptive immune systems in the lungs typically require up to two weeks to respond to the virus, vaccinated mice launched a counter-attack in as little as three days.

Beyond viruses, the vaccine provided protection against bacterial infections. Specifically, it was effective against Staphylococcus aureus and Acinetobacter baumannii. These two types of bacteria are frequently acquired in hospital settings and are noted for becoming increasingly resistant to antibiotics.

Impact on Respiratory Allergies

One of the most unexpected findings of the research was the vaccine’s effect on asthma and allergens. When vaccinated mice were exposed to house dust mites, a common allergen, their asthmatic responses were reduced for three months.

The study found that the vaccine reduced the production of excess lung mucus and the increase of immune cell production typically associated with allergic reactions.

A Shift in Vaccine Mechanism

The development represents a significant shift in immunology. Since the 1790s, vaccines have generally functioned by preparing the immune system to recognize a distinctive component of a specific pathogen. The GLA-3M-052-LS+OVA vaccine instead focuses on the body’s general response to respiratory threats.

I think what we have is a universal vaccine against diverse respiratory threats,

Bali Pulendran, microbiologist at Stanford and senior author of the study

Pulendran suggested that if this technology is translated into humans, it could potentially replace the need for multiple annual injections for seasonal respiratory infections and provide a ready defense against emerging pandemic viruses.

Study Details and Future Outlook

The research was led by Haibo Zhang, a postdoctoral scholar in Pulendran’s lab, who served as the study’s lead author. The findings indicate that a single nasal spray could theoretically protect against a wide spectrum of threats, including influenza, respiratory syncytial virus, the common cold, bacterial pneumonia, and early spring allergens.

While the results in mice are promising, the transition to human application remains a future goal. The ability to provide broad-spectrum protection through a non-invasive nasal delivery system would represent a transformation in medical practice for managing seasonal and acute respiratory illnesses.